Nasdaq

Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, ...
Nasdaq

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...
STAT

Recursion seeks to deliver results, and a VC sees a wave of M&A coming

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...